CorporationActive
[MNDWN] Moondown Pharmaceuticals LLC
7 membersTax 15%Founded in 2018
CEOpompanoIndependent- Kills
- 1
- +0 in the last 90 days
- Losses
- 46
- +0 in the last 90 days
- Efficiency
- ISK Efficiency 9%
- ISK destroyed
- 125.6M
- +0 in the last 90 days
- Activity
- Inactive
- 0 kills/day · last 90 days
Combat Record
Career-long numbers from eve-kill
Combat
- Kills
- 1
- Losses
- 46
- Danger Ratio
- 100%
- Final Blows
- 1
- Points
- 1
ISK
- Destroyed
- 125.6M
- Lost
- 1.33B
- Balance
- -1.20B
- ISK Efficiency
- 9%
Solo
- Solo Kills
- 1
- Solo Ratio
- 100%
- Avg Kills/Day
- —
Other
- NPC Losses
- 0
- NPC Loss Ratio
- 0%
- Activity
- Inactive
Activity
What the corporation flies, where it fights, latest kills and losses
Most Valuable
The priciest kills in the window
Matchups
Who they kill, who kills them, what they lose
Last 90d
Killed
Killed By
Hulls LostLosses broken down by hull class.
Battles
Engagements in the selected window, from our own killmail archive
Description
Moondown Pharmaceuticals LLC - an EXTREMELY limited liability company
"offering an exciting portfolio of options, focused on supporting efforts and providing solutions positioned to simplify process and reduce vendor reliance, and to provide comprehensive directions across facilities with important outcomes derived from this value providing focus"
If you are a member of the news media and have questions about a recent announcement, would like to request an interview or need additional information, please contact a member of Moondown Pharmaceuticals' media relations team.
For recent press releases, see below.
June 10th, 2018 - FOR IMMEDIATE RELEASE
Moondown Pharmaceuticals is voluntarily recalling lot WXT667 of Milkflower Root Injection, USP, 0.9 mg/mL, 1 mL in 2.5 mL, single-use cartridge syringe system to the hospital/institution level due to the potential presence of toxic waste matter inside the syringe cartidges. In the event that impacted product is administered to a patient, the patient has an extremely high likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, septic shock, early death - and extreme toxicity. The risk is reduced by the possibility of detection, as the labeling contains a clear statement directing visual inspection of the product for particulate matter, toxins, discoloration, and presence of GMOs prior to administration. To date, Moondown Pharmaceuticals LLC has received no reports of any adverse events associated with this issue for this lot.
"offering an exciting portfolio of options, focused on supporting efforts and providing solutions positioned to simplify process and reduce vendor reliance, and to provide comprehensive directions across facilities with important outcomes derived from this value providing focus"
If you are a member of the news media and have questions about a recent announcement, would like to request an interview or need additional information, please contact a member of Moondown Pharmaceuticals' media relations team.
For recent press releases, see below.
June 10th, 2018 - FOR IMMEDIATE RELEASE
Moondown Pharmaceuticals is voluntarily recalling lot WXT667 of Milkflower Root Injection, USP, 0.9 mg/mL, 1 mL in 2.5 mL, single-use cartridge syringe system to the hospital/institution level due to the potential presence of toxic waste matter inside the syringe cartidges. In the event that impacted product is administered to a patient, the patient has an extremely high likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, septic shock, early death - and extreme toxicity. The risk is reduced by the possibility of detection, as the labeling contains a clear statement directing visual inspection of the product for particulate matter, toxins, discoloration, and presence of GMOs prior to administration. To date, Moondown Pharmaceuticals LLC has received no reports of any adverse events associated with this issue for this lot.